Evidence-first library
Browse what each entry is, why it is discussed, what kind of evidence exists, and how its regulatory status differs between Canada and the United States. Related compounds are labeled clearly and are never presented as peptides.
GLP-1 receptor agonist
A long-acting GLP-1 analog. Authorized products and gray-market powders are not interchangeable.
Evidence context: Product-specific randomized trials and regulatory reviewRead the evidence and regulatory profileDual GIP / GLP-1 receptor agonist
A synthetic, lipidated peptide that activates GIP and GLP-1 receptors.
Evidence context: Product-specific randomized trials and regulatory reviewRead the evidence and regulatory profileGLP-1 receptor agonist
An acylated GLP-1 analog with established human clinical programs and product labeling.
Evidence context: Established human clinical evidence and product labelingRead the evidence and regulatory profileGIP / GLP-1 / glucagon agonist
An investigational triple-receptor agonist. Trial activity does not equal regulatory approval.
Evidence context: Ongoing and published investigational human trialsRead the evidence and regulatory profileResearch peptide
Human evidence is sparse and inadequate to establish efficacy, dosing, or long-term safety.
Evidence context: Primarily preclinical evidence with sparse human dataRead the evidence and regulatory profileGHRH analog family
The name is used for materially different DAC and non-DAC structures, creating an identity problem.
Evidence context: Limited human pharmacology plus preclinical evidenceRead the evidence and regulatory profileThymosin beta-4 fragment
A short thymosin beta-4-related fragment; it should not be treated as interchangeable with full-length thymosin beta-4.
Evidence context: Preclinical and molecule-adjacent evidenceRead the evidence and regulatory profileCopper-binding tripeptide
A copper complex also called copper tripeptide-1; topical cosmetic and injectable contexts carry very different evidence and risk questions.
Evidence context: Mechanistic, preclinical, and limited topical evidenceRead the evidence and regulatory profileAlpha-MSH-derived tripeptide
A three-amino-acid research peptide whose small size does not remove identity, purity, formulation, or safety questions.
Evidence context: Preclinical evidence without established human exposureRead the evidence and regulatory profileGHRH analog
A growth hormone-releasing factor analog with product-specific clinical evidence and materially different regulatory status by country.
Evidence context: Product-specific clinical trials and a narrow US approvalRead the evidence and regulatory profileGrowth-hormone secretagogue
A synthetic pentapeptide acting at the ghrelin receptor; pharmacodynamic activity is not the same as proven clinical benefit.
Evidence context: Limited human pharmacology plus preclinical evidenceRead the evidence and regulatory profileSynthetic tetrapeptide
Also spelled Epithalon; naming, salt form, identity, and evidence should be checked before comparing reports or claims.
Evidence context: Limited, difficult-to-generalize evidenceRead the evidence and regulatory profileMitochondrial-derived peptide
A mitochondrial-derived research peptide whose biological interest has moved far ahead of human clinical evidence.
Evidence context: Preclinical evidence without established human exposureRead the evidence and regulatory profileLong-acting amylin analog
An investigational amylin analog with human trial evidence but no general marketing authorization in Canada or the United States.
Evidence context: Investigational human clinical evidenceRead the evidence and regulatory profileMelanocortin receptor agonist peptide
Also called PT-141. A specific US prescription product is approved for a narrow indication, while generic research material is not equivalent to that product.
Evidence context: Product-specific US regulatory review and human trialsRead the evidence and regulatory profileSynthetic heptapeptide
A synthetic research peptide also described as selank acetate or TP-7; online claims extend beyond the limited human evidence.
Evidence context: Small, geographically concentrated human comparative evidenceRead the evidence and regulatory profileSynthetic heptapeptide
A synthetic research peptide with limited human evidence and no authorized human drug identified in Canada or the United States.
Evidence context: Limited, setting-specific human clinical evidenceRead the evidence and regulatory profileEndogenous tripeptide
An endogenous tripeptide whose oral, topical, natural-health-product, compounded, and injectable contexts must be kept separate.
Evidence context: Route-, formulation-, product-, and claim-specific human evidenceRead the evidence and regulatory profileNucleotide coenzyme
A peptide-adjacent topic included because it appears in the same communities and vendor catalogs. NAD+ is a coenzyme, not a peptide.
Evidence context: Related-compound context with limited human intervention evidenceRead the evidence and regulatory profile